Document is current
Any future updates will be listed below
-
Authors
Ställberg, Björn https://orcid.org/0000-0001-8497-7326
Janson, Christer
Lisspers, Karin
Johansson, Gunnar
Gutzwiller, Florian S. https://orcid.org/0000-0001-7754-5744
Mezzi, Karen
Bjerregaard, Bine Kjoeller https://orcid.org/0000-0002-5233-5481
Kejs, Anne Mette Tranberg
Jorgensen, Leif
Larsson, Kjell
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 23 September 2020
First Online: 20 October 2020
Competing interests
: B.S. reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, Meda, Teva, and Chiesi, outside the submitted work. C.J. reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Teva, outside the submitted work. K. Lisspers reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, and Chiesi, outside the submitted work. G.J. has participated in the steering committee organised by Novartis for this study and served on advisory boards arranged by AstraZeneca, Novo Nordisk, and Takeda. F.S.G. and K.M. are employees of Novartis Pharma AG. B.K.B., L.J., and A.M.T.K. are employees of IQVIA and have received remuneration in relation to statistical analyses. K. Larsson has, during the past 5 years, on one or more occasion served in an advisory board, served as a speaker, and/or participated in education activities arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Sanofi, Novartis, Orion, and Teva.
